Thomson Reuters Foundation

Inform - Connect - Empower

FACTBOX-Top-selling drugs for ultra-rare diseases

Source: Thomson Reuters Foundation - Thu, 3 Jan 2013 14:11 GMT
Author: Reuters
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

Jan 3 (Reuters) - Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year.

The following are among the top-selling treatments for extremely rare disorders:

Soliris, Alexion Pharmaceuticals

- Treatment for a progressive disease that destroys red blood cells and a second condition that damages the kidney and other vital organs.

Forecast 2012 sales: ${esc.dollar}1.1 billion.

Cerezyme, Sanofi

- Drug to help break down fatty clumps that build up in cells in patients with Gaucher disease, damaging the liver, spleen and bones.

Forecast 2012 sales: ${esc.dollar}830 million

Myozyme, Sanofi

- Treats Pompe disease, an inherited neuromuscular disorder that causes progressive muscle weakness.

Forecast 2012 sales: ${esc.dollar}580 million

Elaprase, Shire

- Treatment for Hunter syndrome, a genetic disease that primarily affects males, causing serious physical and mental problems.

Forecast 2012 sales: ${esc.dollar}495 million

Fabrazyme, Sanofi

- Fabry disease treatment designed to counter damaging symptoms including kidney failure, heart problems and stroke.

Forecast 2012 sales: ${esc.dollar}352 million

Cinryze, ViroPharma

- Prevents dangerous swelling and painful attacks in people with hereditary angioedema.

Forecast 2012 sales: ${esc.dollar}330 million

Vpriv, Shire

- Treatment for Gaucher disease.

Forecast 2012 sales: ${esc.dollar}310 million

Kalydeco, Vertex Pharmaceuticals

- For treating a rare form of the lung disease cystic fibrosis in patients with a particular genetic mutation.

Forecast 2012 sales: ${esc.dollar}260 million

Naglazyme, Biomarin Pharmaceutical

- Treatment for Maroteaux-Lamy syndrome, which causes short stature, stiff joints and breathing problems.

Forecast 2012 sales: ${esc.dollar}233 million

Source: sales figures based on analyst forecasts compiled by Thomson Reuters (Reporting by Ben Hirschler; editing by David Stamp)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular

Latest slideshow

See allSee all
Featured jobs